Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.

Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008 Oct 15; 14(20):6697-703.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.